Iberdomide (Zenbexus) wins accelerated approval in relapsed myeloma — and five sponsors already run combinations built on it

Bristol Myers Squibb's iberdomide reached the US market on an accelerated approval in multiple myeloma that has returned or stopped responding to prior treatment, under the brand name Zenbexus, as reported by Endpoints News on 13 August 2026 ^[1]. Prognyx located no FDA primary record for this action in the sources reviewed: no Drugs@FDA entry, no approval letter, no label, no agency announcement. The exact agency action date, the approved indication wording, whether the clearance covers iberdomide alone or in a combination, the required prior therapy and the endpoint that carried the file are therefore unverified, and that caveat governs everything below.

What happened

Iberdomide is a CRL4(CRBN) E3 ubiquitin ligase modulator ^[2] — the same cereblon machinery lenalidomide and pomalidomide engage, retuned for deeper degradation of Ikaros and Aiolos ^[15]. ChEMBL still carries the compound at maximum phase 3 ^[2], a fair measure of how far ahead of the reference databases a press-reported approval runs.

The Endpoints item is the only account of this clearance Prognyx can cite to a durable publisher URL, and the excerpt available to us is truncated at the list price — so no price figure appears anywhere in this briefing ^[1].

The franchise math BMS filed years ago

This is not an opportunistic clearance. It is the execution of a plan BMS put in front of investors five years ago. The Q2 2021 earnings presentation listed iberdomide plus dexamethasone in fourth-line-plus myeloma as a phase 1b/2a data set in hand, and placed the asset in the block of mid-to-late-stage growth opportunities behind a launch portfolio the company sized at $20–25B of non-risk-adjusted revenue potential in 2029 ^[5]. The January 2022 JP Morgan deck raised that framing to $25B+, named iberdomide among the launches meant to deliver it, and defined Revlimid, Abraxane, Sprycel and Pomalyst as the key loss-of-exclusivity brands ^[6]. The Q4 2021 deck committed to initiating the second-line-plus phase 3, EXCALIBER ^[4].

Those are 2021 and 2022 forward-looking statements, not current guidance, and Prognyx does not treat them as such. What they establish is intent, in writing, with a date: the CELMoD program was built to stand where Revlimid and Pomalyst stood. With the approval reported on 13 August 2026, that thesis is finally testable.

The randomized evidence

EXCALIBER-RRMM (NCT04975997) is the randomized phase 3 of the iberdomide triplet: open-label, two-stage, 939 patients, iberdomide with daratumumab and dexamethasone against daratumumab with bortezomib and dexamethasone, started 23 June 2022, with co-primary endpoints of progression-free survival and minimal residual disease–negative complete response at any time ^[3]. It is active but no longer recruiting, its primary completion date is 16 November 2027, and no results are posted ^[3]. Whether it is the trial that supported the clearance is not established in the record reviewed.

A June 2026 congress plenary and oral abstracts record (Europe PMC PMC13254486) includes iberdomide data; no efficacy figure was retrievable from it for this briefing ^[17].

Accelerated approval is a clock, not a conclusion — as a matter of general US regulatory framework rather than anything sourced about this particular file, it converts a surrogate endpoint into a marketing authorization against an obligation to verify clinical benefit in a confirmatory study. Convert that into a calendar. The only randomized phase 3 of iberdomide in relapsed or refractory disease in the record here has a primary completion date of 16 November 2027 ^[3]. If EXCALIBER serves as the confirmatory study — a link no source here establishes — that date marks when the co-primary endpoints can be assessed, not when data become public; lock, analysis and a congress or journal slot conventionally push disclosure into the first half of 2028. Prognyx's working window for confirmatory data is therefore late 2027 to mid-2028, with the assumptions stated. Until then, the randomized comparison of iberdomide/daratumumab/dexamethasone against daratumumab/bortezomib/dexamethasone stays unpublished ^[3].

Who is exposed — by name

The exposure runs in two directions at once, and the registry shows both.

Pfizer is the cleanest case: MagnetisMM-30 (NCT06215118) is a phase 1 of its BCMA bispecific elranatamab with oral iberdomide dosed once daily for 21 of every 28 days, 87 patients, recruiting, started 20 February 2024, primary completion 10 April 2027 ^[8]. AbbVie pairs intravenous etentamig with an oral CELMoD — iberdomide — in a phase 1/2 (the registry listing also carries it as phase 1) of roughly 135 participants across about 50 sites, recruiting since 7 August 2025, with primary completion listed as March 2036, against a stated study duration of about 129 months ^[10]. The National Cancer Institute is running teclistamab with iberdomide in a 26-patient phase 1b whose stated job is to define the recommended phase 2 dose and maximum tolerated dose of iberdomide in that pairing, primary completion 31 December 2026 ^[9]. The Alliance for Clinical Trials in Oncology is testing iberdomide with belantamab mafodotin — a BCMA-binding agent at maximum phase 4 in ChEMBL ^[13] — plus dexamethasone in 88 patients, primary completion 1 May 2028 ^[11]. And BMS's own Juno unit is combining arlocabtagene autoleucel, its CAR-T, with alnuctamab, mezigdomide, iberdomide, elranatamab and dexamethasone in 187 patients, primary completion 1 August 2028 ^[7].

These are registry listings. They state what is being tested and nothing about how well it works, and none is described in the record as registration-directed.

The counter-pressure is that lenalidomide has not moved. BMS is attacking that flank itself — NCT05827016 is a phase 3 of iberdomide maintenance versus lenalidomide maintenance after autologous transplant in newly diagnosed patients, active but no longer recruiting ^[19]. Meanwhile lenalidomide remains the backbone in live academic protocols, including M.D. Anderson's MRD-guided phase 2 pairing belantamab mafodotin with lenalidomide in 94 newly diagnosed patients, primary completion 31 December 2027 ^[12] — and in Biogen's felzartamab, whose first global approval, in China for second-line myeloma reported by Endpoints on 14 August 2026, is alongside lenalidomide and dexamethasone ^[14]. The anti-CD38-plus-immunomodulator architecture is old ground for this franchise; Celgene's completed phase 2 tested pomalidomide and low-dose dexamethasone with or without daratumumab after lenalidomide-based therapy ^[18].

Any company whose myeloma regimen economics rest on the oral backbone being inexpensive now has a branded alternative to price against — Prognyx's read, not a sourced pricing claim: no patent or pricing data appears in the record reviewed, and the Endpoints list price figure is truncated in the excerpt available to us ^[1]. That is a pricing question and a comparator problem in the same quarter.

What to watch, with dates

• The FDA record itself. A label, approval letter or Drugs@FDA entry would settle the indication wording, the prior-therapy requirement and the confirmatory obligation. Prognyx located none.
• 31 December 2026 — primary completion of the NCI's teclistamab-plus-iberdomide phase 1b, the nearest dated milestone in the combination set ^[9].
• 10 April 2027 — primary completion of Pfizer's MagnetisMM-30 ^[8].
• 16 November 2027 — primary completion of EXCALIBER-RRMM, the earliest point at which the randomized comparison can be assessed ^[3].
• 1 May 2028 and 1 August 2028 — the Alliance belantamab mafodotin combination and BMS's arlocabtagene autoleucel platform ^[11][7].
• Housekeeping that signals reality: whether NCT04975997 and NCT06121843 are amended after the approval, and whether ChEMBL moves iberdomide off phase 3 ^[3][7][2].

A primary completion date is when a trial reaches the assessment point for its primary endpoints. It is not a readout date, and none of the dates above is a disclosure commitment.

The now-what

Re-cost the oral partner. If a bispecific, ADC or CAR-T plan is costed on the assumption that its oral companion stays inexpensive, that assumption now has a branded alternative that a competitor's own trial protocol may prefer — Prognyx's inference; see what we could not verify. Model both the combination economics and the partnering conversation with BMS, because five sponsors are already in that conversation ^{[8][10][9][11][7]}.

Do not model efficacy from the approval. The supporting endpoint is not public and the only randomized comparison, EXCALIBER, is unread ^[3]. Comparator arms should be designed against what is published, not against a regimen whose effect size is absent from the public record.

Compete on tolerability. Immunomodulators delivered the survival gains that let many myeloma patients live ten years or longer, which is precisely why treatment-related toxicity — peripheral neuropathy above all — has become decisive in regimen choice ^[16]. In an incurable disease whose frontline strategies increasingly use quadruplets ^[15], a partner that spares neuropathy has a claim that does not require beating anyone on response rate.

What Prognyx could not verify

No FDA primary source for this approval was located: no Drugs@FDA record, approval letter, label or agency announcement, which leaves the indication wording, whether the clearance covers iberdomide alone or in combination, the required prior lines, any warnings and the dosing schedule unverified. The exact agency action date could be 12 or 13 August 2026. No BMS press release and no SEC filing covering the approval appears in the sources reviewed — the three BMS filings cited here are 2021 and 2022 pipeline decks. Several same-day and earlier trade-press items on this programme were available to Prognyx only as news-aggregator redirects carrying headlines with no retrievable body text and no canonical publisher URL; none is cited, and no claim in this briefing rests on them — which is why no filing date, no review-speed arithmetic and no prior-readout characterisation appears above. The Endpoints excerpt available to us is truncated at the list price, so no price figure is printed anywhere in this briefing, and no patent or pricing data for any myeloma oral agent is in the record. Which trial and which surrogate endpoint supported the clearance, and whether EXCALIBER is the mandated confirmatory study, are not established. Precedence — whether iberdomide is the first next-generation CELMoD to market — is not established either; the class framing is sourced ^[15], the ranking is not. EU status is absent from the record.

Verdict. Threat level: high for anyone whose myeloma combination economics rest on an inexpensive oral backbone — Prognyx's read, not a sourced pricing claim — and moderate for BCMA developers, who gain a partner at the same moment they gain a landlord. Window to act: now, while the label and the supporting endpoint are still not public — that window closes the moment the FDA record posts, and long before 16 November 2027 ^[3].